Cancer drug maker BiPar sells to Sanofi-aventis for $500M

Cancer drug maker BiPar sells to Sanofi-aventis for $500M

BiPar Sciences, maker of tumor-targeting cancer treatments, will be acquired by public global pharmaceutical company Sanofi-aventis. The two companies have signed a binding agreement that could deliver more than $500 million to BiPar, divided into varying milestone payments.

Based in Brisbane, Calif., BiPar creates therapies, primarily… Continue Reading

BiPar snags $20M for inhibitor-based cancer therapies

Pharmaceutical firm BiPar Sciences just brought in $20 million in private equity and venture debt to advance its lead therapy, targeting breast cancer, to phase-three clinical trials. The investment will double the Brisbane, Calif.-based company’s cash on hand, a huge vote of confidence for its… Continue Reading

Life sciences briefing: Thursday, Nov. 15, 2007

Life sciences briefing: Thursday, Nov. 15, 2007

Featured companies: BioVex, FullTurn Media, Humanetics, N Spine, Novitas Capital, Reliant Technologies, Symbios, Vaxart, Virtual Radiologic, Winston Laboratories, Zosano Pharma

EXPANDING ITEMS: Stay tuned.

Vaxart receives $3.3M for oral vaccines — San Francisco’s Vaxart, a biotech developing novel adenovirus-based vaccines, raised $2.7 million in a first funding round. Vaxart… Continue Reading

Life sciences briefing: Thursday, Sept. 27, 2007

Life sciences briefing: Thursday, Sept. 27, 2007

Featured companies: AstraZeneca, Atlantis Components, Cara Therapeutics, CardioMems, Corium International, New Ortho Polymers, Osprey Pharmaceuticals, Othera Pharmaceuticals, StrataGent Life Sciences

Corium acquires Stratagent, raises $25.1M for “transdermal” drugs — Corium International, a Menlo Park, Calif., biotech focused on drugs that can be delivered through the skin, said… Continue Reading

StrataGent closes $16M round for needle-free injections

StrataGent closes $16M round for needle-free injections

StrataGent Life Sciences, a San Jose developer of needle-free “microjet” injection systems, said it closed a $16 million second round of financing. The company has so far received $6.65 million of that round; the remainder should become available next year if and when StrataGent meets… Continue Reading

BiPar Sciences raises $35M for cancer therapies

BiPar Sciences, Inc., a biopharmaceutical company developing cancer therapies, said it has raised $35 million in a second round of financing.

The round was led by Domain Associates. Existing investors participated, including Vulcan Capital, Canaan Partners, PolyTechnos Venture-Partners, Asset Management Company and Quantum Technology Partners.

BiPar… Continue Reading